C5 and COVID-19: To date, most of the strategies used to target complement activation in COVID-19 have focused on C5 inhibition, in particular using the monoclonal antibody eculizumab, which has already been approved for the treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia gravis and neuromyelitis optica spectrum disorder.